Main Uses and Indications

Фтизоактив is a combination pharmaceutical product primarily used in the treatment of various forms of tuberculosis. Its formulation is designed to act against Mycobacterium tuberculosis, the primary causative agent of the disease. The medication is typically prescribed for:

• Pulmonary Tuberculosis: Treatment of infections affecting the lung tissue, including both newly diagnosed cases and chronic forms.
• Extrapulmonary Tuberculosis: Management of tuberculous infections located in organs and systems outside the lungs, such as the bones, joints, genitourinary system, or peripheral lymph nodes.
• Comprehensive Therapy: Integration into multi-drug regimens to enhance the overall efficacy of the treatment protocol and address bacterial resistance.

Therapeutic Benefits

The components of Фтизоактив work synergistically to provide several clinical benefits during the course of therapy:

Bactericidal and Bacteriostatic Action

The medication inhibits the synthesis of essential components in the bacterial cell wall and interferes with the metabolic processes of the pathogen. This dual action helps to both eliminate actively dividing bacteria and inhibit the growth of those in a dormant state.

Enhanced Treatment Efficacy

By combining multiple active agents, the formulation helps to maintain therapeutic concentrations of the necessary compounds in the blood and tissues. This is intended to improve the clinical response compared to certain monotherapy approaches.

Reduction of Resistance Risk

The use of combination therapy is a standard strategy in tuberculosis management to prevent the development of drug-resistant strains of the bacteria. Фтизоактив supports this goal by providing a multifaceted attack on the pathogen's biological pathways.

Support for Tissue Repair

Effective control of the mycobacterial load allows the body's natural healing processes to begin, potentially reducing the extent of tissue damage and inflammation caused by the chronic infection.

Eligibility Map: Who Can and Cannot Use Фтизоактив — Official Regulatory Information

Populations for whom use is Contraindicated

Use of this fixed-dose combination (FDC) is formally prohibited for individuals with acute liver disease of any cause or a known history of Isoniazid-induced hepatic injury. Hypersensitivity to Isoniazid, Pyridoxine, or any component is an absolute contraindication.

Age-Related and Conditional Eligibility

Eligibility extends to adults, adolescents, and children. However, the FDC tablet may be inappropriate for young children below specified minimum weight or age limits, as the fixed dose does not permit safe adjustment for their body size. Patients over 50 years and those with existing chronic liver disease or severe renal impairment require close clinical and laboratory monitoring due to increased risk of toxicity.

Pregnancy and Lactation Status

Use is generally permitted during pregnancy and breastfeeding, as the benefit of treating the infection usually outweighs the potential risk. Pyridoxine (a component of Фтизоактив) is universally recommended during these periods to address potential drug-induced effects in the mother and infant, as documented in clinical guidelines.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Фтизоактив around agents that significantly modify its systemic exposure or lead to additive effects. This profile outlines specific constraints for co-administration based on the mechanistic classifications of interacting agents.

Interacting Product Category	Mechanistic Basis	Regulatory Constraint/Requirement
Strong CYP Enzyme Inducers	Decreased systemic exposure of Фтизоактив via metabolism induction.	Co-administration is generally restricted or required to be avoided.
Strong CYP Enzyme Inhibitors	Increased systemic exposure of Фтизоактив via metabolism inhibition.	Requires dose adjustment and close clinical monitoring upon initiation or discontinuation.
Agents that Alter Gastric pH	Reduced absorption and oral bioavailability due to pH-dependent dissolution.	A specific time separation is required between the administration of the two products.
Agents with Pharmacodynamic Overlap	Additive effects on specific organ systems or biochemical pathways.	Use with caution, with increased vigilance for signs of cumulative toxicity.

The regulatory statements indicate that the primary clinical risk involves pharmacokinetic interactions that alter the blood concentration of Фтизоактив. Co-administration with strong inducers of cytochrome P450 enzymes is documented as significantly decreasing the drug's exposure. Conversely, strong inhibitors increase exposure, requiring mandated dose modification or enhanced patient monitoring as defined in the official labeling.

Disruption of Mycolic Acid Synthesis

This domain covers the core bactericidal action by interfering with the integrity of the target organism's cell wall. The drug acts as a prodrug and, once activated by bacterial enzymes (specifically a catalase-peroxidase), it initiates signaling sequences that inhibit the synthesis of mycolic acids. This modification of early molecular steps compromises the essential structural components of the bacterial cell wall, inducing predictable physiological adjustments of microbial cell lysis and death.

---

Inhibition of Bacterial Metabolic Processes

This domain involves enzyme-mediated signaling that modulates key pathways necessary for the microbe's growth and survival. The active metabolite of the drug forms adducts, which engage mechanisms that regulate dysregulated bacterial processes by inhibiting enzymes like NADH-dependent enoyl-acyl carrier protein reductase ( InhA). This affects systems where specific cofactors or mediators dominate, modifying the resulting effects of excessive bacterial metabolic activity.

---

️ Modulation of Reactive Oxygen Species Cascade

The drug may also influence cascades where multiple layers of pathway activation occur, specifically by generating free radicals. The activation process yields radical intermediates, which promotes the transition to a more regulated state within targeted intracellular signaling pathways by acting on biological systems within the microbe.

Official Administration Guidelines for Фтизоактив

Фтизоактив is a Fixed-Dose Combination (FDC) tablet containing Isoniazid and Pyridoxine. Its proper use is strictly governed by the long-term, weight-based protocols established for tuberculosis (TB) treatment and prevention.

---

Administration Scope

Category	Instruction
Route of administration	Oral (tablet).
Timing in relation to meals	Should generally be taken on an empty stomach (e.g., 1 hour before or 2 hours after a meal) to optimize drug absorption.
Preparation requirements	Tablets may be crushed and mixed with soft food or liquid for patients, such as young children, who are unable to swallow whole.
Special procedural conditions	Intermittent regimens (e.g., 2-3 times per week) must be provided via Directly Observed Therapy (DOT).

---

Dosing and Scheduling

Dosage is weight-dependent and varies significantly based on the specific regimen and patient age:

• Adult Daily Dose (Active TB): The Isoniazid component is typically 5 mg/kg once daily, not exceeding 300 mg per day.
• Pediatric Dosing: Higher mg/kg doses are used: 10-20 mg/kg daily, depending on the regimen.
• Duration: Use is divided into a multi-month initial phase and a continuation phase, resulting in total courses that can range from 3 to 9 months or more, based on the specific treatment protocol.

Use Protocol

The official instructions structure the use of Фтизоактив as a mandatory, long-term oral regimen that requires precise, weight-based calculations and adherence to scheduled frequency (daily or intermittent). The administration protocol ensures both proper absorption and mandatory control via DOT for non-daily schedules.

Research evidence / Overview of studies for Фтизоактив

---

Evidence for Use in Active Tuberculosis (TB) Disease

Research exploring the management of active Tuberculosis disease utilized comparative studies. Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews have been studied for regimens that include Isoniazid, the core antitubercular agent in this combination. Studies explored the use of the Fixed-Dose Combination (FDC) pill compared to separate tablets, primarily monitoring patient adherence and treatment completion rates, alongside outcomes related to bacteriological conversion. Findings describe patterns observed in the studies where treatment completion and adherence rates were observed in some studies to be higher in FDC groups.

What remains uncertain is the full context of these results; limited information exists comparing the bioequivalence of this specific FDC with its separate components. Additionally, certain analyses have described variability in reported relapse rates across different FDC products; results indicate that drawing broad conclusions about all FDCs uniformly requires caution.

Evidence for Use in Latent Tuberculosis Infection (LTBI) Prevention

Preventive therapy was studied for individuals diagnosed with latent tuberculosis infection (LTBI). Evidence is primarily derived from RCTs and large Systematic Reviews that historically examined Isoniazid monotherapy. These studies focused on measuring the incidence of progression from latent to active disease over long observation periods, often three or more years. Comparative evidence is lacking for this specific FDC versus separate tablets in the context of LTBI outcomes. Also, the long-term effects are not fully established because the necessary follow-up durations are long, and maintaining compliance across extended periods is a reported research limitation.

The Role of Pyridoxine: Integrated Neurological Support

The inclusion of Pyridoxine (Vitamin B₆) in this FDC was studied for its relevance to neurological outcomes during Isoniazid therapy. Pharmacological Studies and Observational Cohort Analyses examined the incidence and severity of peripheral neuropathy. Studies consistently reported a pharmacological interaction that describes the rationale for co-administering Pyridoxine. Findings indicate its co-administration may be important for reducing the measured incidence of peripheral neuropathy in high-risk patient groups (e.g., those with diabetes or malnutrition). Dedicated large-scale comparative trials withholding Pyridoxine are generally not available due to this established rationale.

Key Studies & References

1. Isoniazid Drug Information

Common questions about Фтизоактив (FAQ)

---

Q: What is the benefit of having Pyridoxine in the Фтизоактив tablet?

Studies and official information indicate that Pyridoxine (Vitamin B6) is included as a preventive measure against a possible side effect of the Isoniazid component. Its purpose is to help reduce the measured incidence of peripheral neuropathy, which is a type of nerve damage associated with the primary tuberculosis treatment. This co-administration is based on established pharmacological rationale.

---

Q: What should I do if I miss a dose of Фтизоактив?

Regulatory labeling addresses how to handle missed doses, often advising patients to refer to the specific instructions provided on the patient leaflet or by their prescribing clinician. If the patient is on a Directly Observed Therapy (DOT) regimen, any missed doses should be reported to the supervising healthcare professional. Patients are generally cautioned against taking more than the prescribed amount at one time to compensate for a missed dose.

---

Q: Is it safe to use Фтизоактив during pregnancy or while breastfeeding?

Regulatory documents state that the use of Isoniazid-containing regimens, such as Фтизоактив, is generally permitted during both pregnancy and breastfeeding. In these cases, the clinical benefit of managing or preventing tuberculosis is generally considered to outweigh the potential risks. Additionally, the Pyridoxine component is widely recommended for use during these periods to address neurological risks for the mother.

---

Q: What are the requirements for storing the Фтизоактив tablets?

According to the official product information, Фтизоактив must be stored at Controlled Room Temperature, typically defined as between 15 C and 30 C (59 F and 86 F). The official storage conditions require the container to be tightly closed and protected from air and light to maintain product stability. Official safety instructions emphasize that the medicine must be stored out of the sight and reach of children.

---

Q: What should I do if I get an allergic reaction to Фтизоактив?

Regulatory documents caution that hypersensitivity to any component is a formal contraindication, and severe skin reactions like Stevens-Johnson Syndrome (SJS) are listed as rare but critical risks. Patients experiencing signs of a serious reaction (e.g., a widespread rash, fever, or swelling) are advised in official warnings to seek immediate medical care. Decisions regarding discontinuing the medicine must be made by a qualified healthcare professional.

---

Q: How long does Фтизоактив stay in your system after you stop taking it?

The time required for the body to eliminate the active ingredients is related to the drug's half-life, which is documented in the product's pharmacokinetics section. For the Isoniazid component, the half-life can vary significantly based on an individual's natural rate of metabolism (acetylation status). However, based on the documented half-lives, the drug is typically eliminated from the system within a few hours to a couple of days after the final dose.

How to Store and Dispose of Фтизоактив

Фтизоактив (Isoniazid/Pyridoxine FDC) must be stored and disposed of according to official regulatory labeling to ensure chemical stability and prevent accidental exposure.

---

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature between 15°C and 30°C (59°F and 86°F).
Protection	Keep the product tightly closed in the original container and protect from air and light.
Safety	Keep the medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired tablets should be discarded via an authorized drug take-back program. If a take-back program is unavailable, the alternative is household trash disposal. For this method, the medicine must be mixed with an undesirable substance, placed in a sealed bag or container, and all identifying information on the original label must be scratched out.